Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Renaissance Technologies’ Q2 2025 13F portfolio grew to $75B. Check out the significant stake increases and major reductions ...

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

None of this is surprising — especially when at least 500,000 Brits are currently taking Mounjaro and Wegovy via private prescription. For many, the prospect of going cold turkey or forking out up to ...

The hypothesis was that the Tata brand name denotes trust, so you have every right to win in the consumer space. The brief ...